Net Product Revenue was BridgeBio Pharma’s largest product and service line in fiscal 2025, bringing in $369.97M of $508.45M (73%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Net Product Revenue | — | $5.78M | $369.97M | |||
| Cost Of License, Services, & Royalty Revenue | — | — | $93.80M | |||
| License Revenue | — | — | — | |||
| License & Services Revenue | $9.30M | $131.50M | $33.30M | |||
| Royalty Revenue | — | $169.00K | $11.39M | |||
| Total | $9.30M | $137.45M | $508.45M |
BridgeBio Pharma brought in $508.45M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. BridgeBio Pharma regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $137.45M. Net Product Revenue was the largest at $369.97M (72.8%), ahead of Cost Of License, Services, & Royalty Revenue at $93.80M (18.4%) and License & Services Revenue at $33.30M (6.5%). The remaining line, Royalty Revenue, brought in $11.39M.
Compared with fiscal 2024, Royalty Revenue grew fastest, up 6,637.3% to $11.39M, while License & Services Revenue fell the most, down 74.7% to $33.30M.
BridgeBio Pharma began breaking out Net Product Revenue in fiscal 2024, Cost Of License, Services, & Royalty Revenue in fiscal 2025 and Royalty Revenue in fiscal 2024.
Bayer was BridgeBio Pharma’s largest revenue line in fiscal 2024, bringing in $131.50M of $218.20M (60%).
| Counterparty Name | FY 2021 | FY 2022 | FY 2024 |
|---|---|---|---|
| Bayer | — | — | $131.50M |
| Kyowa Kirin Co., Ltd | — | — | $76.20M |
| Helsinn Therapeutics | $56.00M | — | — |
| Bms | — | — | $9.90M |
| Bms License Agreement | — | $74.70M | — |
| Alexion License Agreements | — | — | $600.00K |
| Total | $56.00M | $74.70M | $218.20M |
BridgeBio Pharma brought in $218.20M from its four revenue lines in fiscal 2024, the year ended December 31, 2024. BridgeBio Pharma regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $74.70M. Bayer was the largest at $131.50M (60.3%), ahead of Kyowa Kirin Co., Ltd at $76.20M (34.9%) and Bms at $9.90M (4.5%). The remaining revenue line, Alexion License Agreements, brought in $600.00K.
BridgeBio Pharma began breaking out Bayer in fiscal 2024, Kyowa Kirin Co., Ltd in fiscal 2024, Bms in fiscal 2024 and Alexion License Agreements in fiscal 2024. BridgeBio Pharma stopped reporting Bms License Agreement ($74.70M in fiscal 2022) and Helsinn Therapeutics ($56.00M in fiscal 2021) as separate revenue lines.
BridgeBio Pharma (BBIO) reports its revenue by product and service and by counterparty name. In fiscal 2025, Net Product Revenue was its largest product and service line, bringing in $369.97M (72.8% of the total), followed by Cost Of License, Services, & Royalty Revenue at $93.80M (18.4%).
Net Product Revenue was BridgeBio Pharma's largest product and service line in fiscal 2025, bringing in $369.97M, or 72.8% of the $508.45M total across its four product and service lines.
Bayer was BridgeBio Pharma's largest revenue line in fiscal 2024, bringing in $131.50M, or 60.3% of the $218.20M total across its four revenue lines.
Every figure comes from BridgeBio Pharma's annual financial filings, as reported. Each line keeps the name BridgeBio Pharma gives it, and years follow its fiscal calendar.
BridgeBio Pharma's revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.